RBC Capital Increases Price Target for Incyte Corporation to $95
RBC Capital raised its price target for Incyte Corporation (NASDAQ:INCY) from $92 to $95 on April 7, 2026, while maintaining a Sector Perform rating. The update was part of a broader analysis of the biotech sector's Q1 fiscal results, noting potential challenges like seasonal headwinds and weather impacts, but also highlighting positive factors such as M&A activity and clarity on drug pricing. Incyte reported strong revenue growth in Q4 2025, with total revenue reaching $1.51 billion for the quarter.
Tickers: $INCY
Topics: biotech Incyte Corporation price target RBC Capital stock analysis